151 related articles for article (PubMed ID: 10720508)
1. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.
Birx DL; Loomis-Price LD; Aronson N; Brundage J; Davis C; Deyton L; Garner R; Gordin F; Henry D; Holloway W; Kerkering T; Luskin-Hawk R; McNeil J; Michael N; Foster Pierce P; Poretz D; Ratto-Kim S; Renzullo P; Ruiz N; Sitz K; Smith G; Tacket C; Thompson M; Tramont E; Yangco B; Yarrish R; Redfield RR
J Infect Dis; 2000 Mar; 181(3):881-9. PubMed ID: 10720508
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to a recombinant human immunodeficiency virus type 1 (HIV-1) gpl60 vaccine among adults with advanced HIV infection. Massachusetts gp160 Working Group.
DeMaria A; Kunches L; Mayer K; Cohen C; Epstein P; Werner B; Day J; DeCristofaro J; Landers S; Tang Y; Coady W
J Hum Virol; 2000; 3(4):182-92. PubMed ID: 10990166
[TBL] [Abstract][Full Text] [Related]
3. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response.
Ratto-Kim S; Sitz KV; Garner RP; Kim JH; Davis C; Aronson N; Ruiz N; Tencer K; Redfield RR; Birx DL
J Infect Dis; 1999 Feb; 179(2):337-44. PubMed ID: 9878016
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunotherapy in HIV infection, combined with short-term antiretroviral treatment.
Bratt G; Eriksson LE; Sandström E; Gilljam G; Hinkula J; Albert J; Redfield R; Wahren B
Int J STD AIDS; 1999 Aug; 10(8):514-21. PubMed ID: 10471100
[TBL] [Abstract][Full Text] [Related]
6. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
[TBL] [Abstract][Full Text] [Related]
7. Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.
Goebel FD; Mannhalter JW; Belshe RB; Eibl MM; Grob PJ; de Gruttola V; Griffiths PD; Erfle V; Kunschak M; Engl W
AIDS; 1999 Aug; 13(12):1461-8. PubMed ID: 10465068
[TBL] [Abstract][Full Text] [Related]
8. Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency.
Tsoukas CM; Raboud J; Bernard NF; Montaner JS; Gill MJ; Rachlis A; Fong IW; Schlech W; Djurdjev O; Freedman J; Thomas R; Lafrenière R; Wainberg MA; Cassol S; O'Shaughnessy M; Todd J; Volvovitz F; Smith GE
AIDS Res Hum Retroviruses; 1998 Apr; 14(6):483-90. PubMed ID: 9566550
[TBL] [Abstract][Full Text] [Related]
9. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
[TBL] [Abstract][Full Text] [Related]
10. Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation Group.
Lambert JS; Viscidi R; Walker MC; Clayman B; Winget M; Wolff M; Schwartz DH
Clin Diagn Lab Immunol; 1997 May; 4(3):302-8. PubMed ID: 9144368
[TBL] [Abstract][Full Text] [Related]
11. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
Gorse GJ; Corey L; Patel GB; Mandava M; Hsieh RH; Matthews TJ; Walker MC; McElrath MJ; Berman PW; Eibl MM; Belshe RB
AIDS Res Hum Retroviruses; 1999 Jan; 15(2):115-32. PubMed ID: 10029244
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough infections during phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160.
Lee D; Graham BS; Chiu YL; Gilbert PB; McElrath MJ; Belshe RB; Buchbinder SP; Sheppard HW; Koblin BA; Mayer KH; Keefer MC; Mulligan MJ; Celum CL
J Infect Dis; 2004 Sep; 190(5):903-7. PubMed ID: 15295694
[TBL] [Abstract][Full Text] [Related]
13. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls.
Sitz KV; Ratto-Kim S; Hodgkins AS; Robb ML; Birx DL
J Infect Dis; 1999 Apr; 179(4):817-24. PubMed ID: 10068576
[TBL] [Abstract][Full Text] [Related]
14. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. NIAID AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Patel G; Newman FK; Belshe RB
Vaccine; 1994 Aug; 12(10):912-8. PubMed ID: 7975833
[TBL] [Abstract][Full Text] [Related]
15. Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
Schooley RT; Spino C; Kuritzkes D; Walker BD; Valentine FA; Hirsch MS; Cooney E; Friedland G; Kundu S; Merigan TC; McElrath MJ; Collier A; Plaeger S; Mitsuyasu R; Kahn J; Haslett P; Uherova P; deGruttola V; Chiu S; Zhang B; Jones G; Bell D; Ketter N; Twadell T; Chernoff D; Rosandich M
J Infect Dis; 2000 Nov; 182(5):1357-64. PubMed ID: 11023459
[TBL] [Abstract][Full Text] [Related]
16. Detection of binding antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins following recombinant gp160 immunization measured by flow cytometry and enzyme immunoassays. The AIDS Vaccine Clinical Trials Network.
Gorse GJ; Frey SE; Newman FK; Belshe RB
J Clin Microbiol; 1992 Oct; 30(10):2606-12. PubMed ID: 1400960
[TBL] [Abstract][Full Text] [Related]
17. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
[TBL] [Abstract][Full Text] [Related]
18. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
Gorse GJ; Simionescu RE; Patel GB
Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
[TBL] [Abstract][Full Text] [Related]
19. Prospective analyses of HIV-1-specific proliferative responses, recall antigen proliferative responses, and clinical outcomes in an HIV-1-seropositive cohort.
Ratto-Kim S; Garner RP; Kim JH; Jagodzinski LL; Michael NL; Paris R; Redfield RR; Birx DL
J Infect Dis; 2004 Jun; 189(11):1988-95. PubMed ID: 15143464
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.
Gilbert PB; Ackers ML; Berman PW; Francis DP; Popovic V; Hu DJ; Heyward WL; Sinangil F; Shepherd BE; Gurwith M
J Infect Dis; 2005 Sep; 192(6):974-83. PubMed ID: 16107949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]